[23:26:28] **▸ Setup**
    Starting the run: as_of 2021-01-01 · single_shot · llm live.

[23:26:28] **🔎 A1 · Why now · retrieve**
    I searched for evidence and kept 19 document(s). These are the only sources I may cite.
    Newest documents:
       • Ensifentrine Phase 3 (ENHANCE-1) [fx:nct-enhance1, 2020-09-01]
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • ETHOS: triple therapy reduces exacerbations, mortality signal [fx:pm-ethos-2020, 2020-06-24]
       • Mepolizumab in COPD (MATINEE) [fx:nct-matinee, 2019-10-01]
       • Type 2 inflammation in a subset of COPD [fx:pm-type2-copd-2019, 2019-06-12] (+14 more)

[23:26:28] **📝 A1 · Why now · prompt**
    I wrote the prompt: 2 messages, about 6,977 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:27:04] **🤖 A1 · Why now · llm**  _35473 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 35473 ms, 1955 tokens in / 4335 out, finish reason 'stop'.
    Start of its raw answer: “{ "shifts": [ { "on": "2019-03-10", "type": "endpoint", "effect_on": ["time", "cost"], "summary": "Annualised moderate/severe exacerbation rate accepted as primary endpoint for COPD add-on biologics; eosinophil enrichme…”
    Its reasoning (first lines): “We need to output JSON with shifts and segments. Must include at least 3 shifts, one negative. Use only evidence pack. AS_OF_DATE 2021-01-01, lookback from 2016-01-01. So shifts between 2016 and 2021. We have evidence from 2016-11-01 (danirixin 2b terminated) to 2020-09-01 (ENHANCE-1). Also earlier…”

[23:27:04] **🧩 A1 · Why now · parse**
    The answer matches the expected schema. It proposes 5 shifts and 3 patient segments.

[23:27:04] **✅ A1 · Why now · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:27:04] **📏 A1 · Why now · validate**
    The output passes this agent's own quality bars.

[23:27:04] **💾 A1 · Why now · commit**
    Saved. Why now: 5 shifts in the disease landscape.
       • 2019-03-10 · endpoint: Annualised moderate/severe exacerbation rate accepted as primary endpoint for COPD add-on biologics; eosinophil enrichment reduces requi…
       • 2018-11-15 · segment: GOLD 2019 formalises blood eosinophil count >=300 cells/uL as a biomarker-defined segment that benefits from ICS; this segment is now use…
       • 2019-05-20 · negative: Benralizumab (anti-IL5RA) failed to reduce exacerbations in eosinophilic COPD despite eosinophil depletion, and FDA declined mepolizumab…
       • 2020-06-24 · negative: Triple therapy (ICS/LAMA/LABA) becomes standard of care with mortality benefit (ETHOS) and multiple approvals; any new add-on must be te…
       • 2018-08-02 · trial_tool: Quantitative CT imaging identifies COPD subtypes and predicts progression, proposed as an enrichment tool to select patients for trial…
    Patient segments: Eosinophilic frequent exacerbator on triple therapy, Type 2 inflammation high with chronic bronchitis, CT-defined airway-predominant with exacerbation history

[23:27:04] **🔎 A2 · Mechanisms · retrieve**
    I searched for evidence and kept 27 document(s). These are the only sources I may cite.
    Newest documents:
       • Open Targets association release [fx:ot-2020-11, 2020-11-18]
       • ChEMBL: ensifentrine [fx:chembl-ensifentrine, 2020-10-01]
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • ETHOS: triple therapy reduces exacerbations, mortality signal [fx:pm-ethos-2020, 2020-06-24]
       • ChEMBL: tezepelumab [fx:chembl-tezepelumab, 2020-06-01] (+22 more)
    Also pulled 13 Open Targets associations and 9 known drugs.

[23:27:04] **📝 A2 · Mechanisms · prompt**
    I wrote the prompt: 2 messages, about 14,344 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:28:14] **🤖 A2 · Mechanisms · llm**  _70338 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 70338 ms, 4440 tokens in / 7136 out, finish reason 'stop'.
    Start of its raw answer: “{ "cards": [ { "id": "h1", "mechanism": "IL33/ST2 axis inhibition", "target_ids": ["hgnc:IL33", "hgnc:IL1RL1"], "direction": "inhibit", "evidence_tier": 3, "validation_level": "silver", "modality": "antibody", "tractabi…”
    Its reasoning (first lines): “We need produce JSON with 6 cards. Need address reviewer feedback: why COPD, which drugs, which companies. But output only JSON? User says "Return only JSON". But also "REVIEWER FEEDBACK (address this explicitly)" maybe we need incorporate in cards? We can include in card fields? The schema likely …”

[23:28:14] **🧩 A2 · Mechanisms · parse**
    The answer matches the expected schema. It proposes 6 mechanism cards.

[23:28:14] **🏷️ A2 · Mechanisms · grade**
    I graded the proposed mechanisms in code (evidence tier, validation level, tractability): 5 kept, 0 rejected.
       • #1 h3 · tier 1/gold · IL4R/IL13 blockade
       • #2 h4 · tier 1/gold · PDE4B/D inhibition
       • #3 h5 · tier 1/gold · PDE3/PDE4 dual inhibition
       • #4 h1 · tier 2/silver · IL33/ST2 axis inhibition
       • #5 h2 · tier 2/silver · TSLP inhibition

[23:28:14] **✅ A2 · Mechanisms · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:28:14] **💾 A2 · Mechanisms · commit**
    Saved 5 ranked hypothesis cards; they will now go through A3 → A6 one at a time.
       • h3: IL4R/IL13 blockade (targets hgnc:IL4R, hgnc:IL13, inhibit)
       • h4: PDE4B/D inhibition (targets hgnc:PDE4B, hgnc:PDE4D, inhibit)
       • h5: PDE3/PDE4 dual inhibition (targets hgnc:PDE3A, hgnc:PDE4B, hgnc:PDE4D, inhibit)
       • h1: IL33/ST2 axis inhibition (targets hgnc:IL33, hgnc:IL1RL1, inhibit)
       • h2: TSLP inhibition (targets hgnc:TSLP, inhibit)

[23:28:14] **🔎 A3 · Product profile · h3 · retrieve**
    I searched for evidence and kept 13 document(s). These are the only sources I may cite.
    Newest documents:
       • Ensifentrine Phase 3 (ENHANCE-1) [fx:nct-enhance1, 2020-09-01]
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • Mepolizumab in COPD (MATINEE) [fx:nct-matinee, 2019-10-01]
       • Type 2 inflammation in a subset of COPD [fx:pm-type2-copd-2019, 2019-06-12]
       • Dupilumab in COPD with type 2 inflammation (BOREAS) [fx:nct-boreas, 2019-04-01] (+8 more)

[23:28:14] **🔎 A3 · Product profile · h4 · retrieve**
    I searched for evidence and kept 13 document(s). These are the only sources I may cite.
    Newest documents:
       • Ensifentrine Phase 3 (ENHANCE-1) [fx:nct-enhance1, 2020-09-01]
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • Mepolizumab in COPD (MATINEE) [fx:nct-matinee, 2019-10-01]
       • Dupilumab in COPD with type 2 inflammation (BOREAS) [fx:nct-boreas, 2019-04-01]
       • FDA declines mepolizumab COPD approval [fx:pm-crl-mepo-2018, 2018-09-07] (+8 more)

[23:28:14] **🔎 A3 · Product profile · h5 · retrieve**
    I searched for evidence and kept 13 document(s). These are the only sources I may cite.
    Newest documents:
       • Ensifentrine Phase 3 (ENHANCE-1) [fx:nct-enhance1, 2020-09-01]
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • Mepolizumab in COPD (MATINEE) [fx:nct-matinee, 2019-10-01]
       • Dupilumab in COPD with type 2 inflammation (BOREAS) [fx:nct-boreas, 2019-04-01]
       • FDA declines mepolizumab COPD approval [fx:pm-crl-mepo-2018, 2018-09-07] (+8 more)

[23:28:14] **🔎 A3 · Product profile · h1 · retrieve**
    I searched for evidence and kept 13 document(s). These are the only sources I may cite.
    Newest documents:
       • Ensifentrine Phase 3 (ENHANCE-1) [fx:nct-enhance1, 2020-09-01]
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • Mepolizumab in COPD (MATINEE) [fx:nct-matinee, 2019-10-01]
       • Dupilumab in COPD with type 2 inflammation (BOREAS) [fx:nct-boreas, 2019-04-01]
       • FDA declines mepolizumab COPD approval [fx:pm-crl-mepo-2018, 2018-09-07] (+8 more)

[23:28:14] **🔎 A3 · Product profile · h2 · retrieve**
    I searched for evidence and kept 13 document(s). These are the only sources I may cite.
    Newest documents:
       • Ensifentrine Phase 3 (ENHANCE-1) [fx:nct-enhance1, 2020-09-01]
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • Mepolizumab in COPD (MATINEE) [fx:nct-matinee, 2019-10-01]
       • Dupilumab in COPD with type 2 inflammation (BOREAS) [fx:nct-boreas, 2019-04-01]
       • Quantitative CT as a trial enrichment tool in COPD [fx:pm-ct-imaging-2018, 2018-08-02] (+8 more)

[23:28:15] **📝 A3 · Product profile · h3 · prompt**
    I wrote the prompt: 2 messages, about 6,536 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:28:15] **📝 A3 · Product profile · h4 · prompt**
    I wrote the prompt: 2 messages, about 6,166 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:28:15] **📝 A3 · Product profile · h5 · prompt**
    I wrote the prompt: 2 messages, about 6,189 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:28:15] **📝 A3 · Product profile · h1 · prompt**
    I wrote the prompt: 2 messages, about 6,479 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:28:15] **📝 A3 · Product profile · h2 · prompt**
    I wrote the prompt: 2 messages, about 6,121 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:28:44] **🤖 A3 · Product profile · h4 · llm**  _29474 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 29474 ms, 1839 tokens in / 4254 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h4", "soc_gap_at_launch": "By 2026-2028, standard of care for COPD with exacerbation history will be single-inhaler triple therapy (ICS/LAMA/LABA) based on approvals of Trelegy (2017) and Breztri (20…”
    Its reasoning (first lines): “We need to produce a TPP for hypothesis h4: PDE4B/D inhibition for COPD. The task is to write a TPP with sections: soc_gap_at_launch, minimum_specs, holy_grail_specs, must_haves, expansion_opportunity. Must use only evidence pack and input. Also address reviewer feedback: "why copd, which drugs sho…”

[23:28:47] **🤖 A3 · Product profile · h5 · llm**  _31964 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 31964 ms, 1860 tokens in / 4480 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h5", "soc_gap_at_launch": "By 2026-2028, standard of care for COPD will include inhaled triple therapy (ICS/LAMA/LABA) as backbone for frequent exacerbators (approved: Trelegy, Breztri) and oral rofl…”
    Its reasoning (first lines): “We need to produce a TPP for hypothesis h5: PDE3/PDE4 dual inhibition, inhaled small molecule, for COPD. We must use only evidence pack and input. The reviewer feedback asks: "why copd, which drugs should i look at, and which companies?" This is likely a prompt to address in the TPP? But the TPP sc…”

[23:29:03] **🤖 A3 · Product profile · h3 · llm**  _48586 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 48586 ms, 1973 tokens in / 5287 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h3", "soc_gap_at_launch": "At launch (~2026-2028), standard of care for symptomatic COPD with exacerbation history will be single-inhaler triple therapy (ICS/LAMA/LABA) based on approvals of Trelegy …”
    Its reasoning (first lines): “We need to produce a TPP for hypothesis h3: IL4R/IL13 blockade (inhibit) for COPD. We must use only evidence pack and input. We need to address reviewer feedback: "why copd, which drugs should i look at, and which companies?" That feedback is likely from a user asking for rationale and drug/company…”

[23:29:10] **🤖 A3 · Product profile · h2 · llm**  _23023 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 23023 ms, 1822 tokens in / 4239 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h2", "soc_gap_at_launch": "By 2026-2028, standard of care for COPD will include inhaled triple therapy (ICS/LAMA/LABA) from GSK (Trelegy) and AstraZeneca (Breztri), and oral roflumilast (Daliresp) fo…”
    Its reasoning (first lines): “We need to produce a TPP for hypothesis h2: TSLP inhibition for COPD. The task is to write a Target Product Profile (TPP) with sections: soc_gap_at_launch, minimum_specs, holy_grail_specs, must_haves, expansion_opportunity. We must use only evidence pack and input. We need to address reviewer feedb…”

[23:29:13] **🤖 A3 · Product profile · h1 · llm**  _29161 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 29161 ms, 1931 tokens in / 6020 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h1", "soc_gap_at_launch": "At launch (~2026-2028), standard of care will include inhaled triple therapy (ICS/LAMA/LABA) as backbone (fx:fda-trelegy-2017, fx:fda-breztri-2020), with roflumilast for se…”
    Its reasoning (first lines): “We need to produce a TPP for IL33/ST2 inhibition in COPD. The hypothesis card is h1, mechanism IL33/ST2 axis inhibition, antibody modality. We need to write a TPP with sections: soc_gap_at_launch, minimum_specs, holy_grail_specs, must_haves, expansion_opportunity. Use only evidence pack and input. …”

[23:29:13] **🧩 A3 · Product profile · h3 · parse**
    The answer matches the expected schema. It lists 2 must-have(s).

[23:29:13] **🧩 A3 · Product profile · h4 · parse**
    The answer matches the expected schema. It lists 2 must-have(s).

[23:29:13] **🧩 A3 · Product profile · h5 · parse**
    The answer matches the expected schema. It lists 2 must-have(s).

[23:29:13] **🧩 A3 · Product profile · h1 · parse**
    The answer matches the expected schema. It lists 2 must-have(s).

[23:29:13] **🧩 A3 · Product profile · h2 · parse**
    The answer matches the expected schema. It lists 2 must-have(s).

[23:29:13] **📏 A3 · Product profile · h3 · validate**
    The output passes this agent's own quality bars.

[23:29:13] **📏 A3 · Product profile · h4 · validate**
    The output passes this agent's own quality bars.

[23:29:13] **📏 A3 · Product profile · h5 · validate**
    The output failed 1 quality bar(s); I'll send them back to the model once:
       • must-have 'no increase in major adverse cardiac events (MACE) vs placebo' is not measurable: name an endpoint, effect size, dosing or safety threshold

[23:29:13] **🔧 A3 · Product profile · h5 · fix**
    1 problem(s) appended to the prompt. Calling the model again with that note.

[23:29:13] **📏 A3 · Product profile · h1 · validate**
    The output passes this agent's own quality bars.

[23:29:13] **📏 A3 · Product profile · h2 · validate**
    The output passes this agent's own quality bars.

[23:30:20] **🤖 A3 · Product profile · h5 · llm**  _66298 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 66298 ms, 1902 tokens in / 16000 out, finish reason 'length'.
       ⚠ the answer was cut off (hit max_tokens); parsing will probably fail.
    Its reasoning (first lines): “We need to produce a Target Product Profile (TPP) for hypothesis h5: PDE3/PDE4 dual inhibition for COPD. The output must be JSON matching the ProductProfile schema. We need to address the reviewer feedback: the must-have 'no increase in major adverse cardiac events (MACE) vs placebo' is not measura…”

[23:30:20] **🧩 A3 · Product profile · h5 · parse**
    The answer was not valid JSON for the schema, so I'll give the model the error and retry once.
       1 validation error for ProductProfile Invalid JSON: EOF while parsing a value at line 1 column 0 [type=json_invalid, input_value='', input_type=str] For further information visit https://errors.pydantic.dev/2.11/v/json_invalid

[23:30:20] **🔧 A3 · Product profile · h5 · fix**
    schema error appended to the prompt. Calling the model again with that note.

[23:30:46] **🤖 A3 · Product profile · h5 · llm**  _26046 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 26046 ms, 1981 tokens in / 5299 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h5", "soc_gap_at_launch": "By 2026-2028, standard of care for COPD is expected to include single-inhaler triple therapy (ICS/LABA/LAMA) as the backbone for patients with exacerbation history (based o…”
    Its reasoning (first lines): “We need to produce a JSON object matching the ProductProfile schema. The user gave feedback: must-have 'no increase in major adverse cardiac events (MACE) vs placebo' is not measurable: name an endpoint, effect size, dosing or safety threshold. So we need to make that measurable. Also we need to ad…”

[23:30:46] **🧩 A3 · Product profile · h5 · parse**
    The answer matches the expected schema. It lists 2 must-have(s).

[23:30:46] **📏 A3 · Product profile · h5 · validate**
    The output passes this agent's own quality bars.

[23:30:46] **✅ A3 · Product profile · h3 · postcheck**
    Citation check made 6 change(s): the model cited things it wasn't given, or claimed too much.
       • a3-h3-002: removed unknown source(s) fx:pm-dupi-asthma-2018
       • a3-h3-002: no valid source left, so it is now 'reasoning' with confidence capped at 0.5
       • a3-h3-003: removed unknown source(s) fx:chembl-dupilumab
       • a3-h3-003: no valid source left, so it is now 'reasoning' with confidence capped at 0.5
       • a3-h3-004: removed unknown source(s) fx:ot-2020-11 (+1 more)

[23:30:46] **✅ A3 · Product profile · h4 · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:30:46] **✅ A3 · Product profile · h5 · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:30:46] **✅ A3 · Product profile · h1 · postcheck**
    Citation check made 4 change(s): the model cited things it wasn't given, or claimed too much.
       • a3-h1-003: removed unknown source(s) fx:ot-2020-11
       • a3-h1-003: no valid source left, so it is now 'reasoning' with confidence capped at 0.5
       • a3-h1-004: removed unknown source(s) fx:chembl-itepekimab, fx:chembl-astegolimab
       • a3-h1-004: no valid source left, so it is now 'reasoning' with confidence capped at 0.5

[23:30:46] **✅ A3 · Product profile · h2 · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:30:46] **💾 A3 · Product profile · h3 · commit**
    Saved the product profile. The product must have:
       • >=30% reduction in annualised moderate/severe exacerbation rate vs placebo on top of triple therapy in patients with blood eos >=300 cells/uL (primary endpoint…
       • No increase in serious adverse events vs placebo (upper bound of 95% CI for SAE rate <1.5)
    Gap in standard of care at launch: At launch (~2026-2028), standard of care for symptomatic COPD with exacerbation history will be single-inhaler triple therapy (ICS/LAMA/LABA) based on approvals of Trelegy (fx:fda-trelegy-2017) and B…

[23:30:46] **💾 A3 · Product profile · h4 · commit**
    Saved the product profile. The product must have:
       • >=25% reduction in annualized moderate/severe exacerbation rate vs placebo on top of triple therapy in patients with chronic bronchitis and >=2 moderate or >=1…
       • Discontinuation rate due to GI adverse events <=10% at 52 weeks
    Gap in standard of care at launch: By 2026-2028, standard of care for COPD with exacerbation history will be single-inhaler triple therapy (ICS/LAMA/LABA) based on approvals of Trelegy (2017) and Breztri (2020) and IMPACT evidence (fx…

[23:30:46] **💾 A3 · Product profile · h5 · commit**
    Saved the product profile. The product must have:
       • Efficacy: At least 20% reduction in annualized moderate/severe exacerbation rate vs placebo on top of triple therapy in patients with FEV1 30-70% predicted and…
       • Safety: No increase in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) with an upper bound of the 95% CI for the hazard ratio vs placebo ≤1.5.
    Gap in standard of care at launch: By 2026-2028, standard of care for COPD is expected to include single-inhaler triple therapy (ICS/LABA/LAMA) as the backbone for patients with exacerbation history (based on approvals of Trelegy [fx:…

[23:30:46] **💾 A3 · Product profile · h1 · commit**
    Saved the product profile. The product must have:
       • ≥25% reduction in annualized moderate/severe exacerbation rate vs placebo on top of triple therapy in patients with ≥2 moderate or ≥1 severe exacerbation in pr…
       • Subcutaneous dosing every 4 weeks or less frequent.
    Gap in standard of care at launch: At launch (~2026-2028), standard of care will include inhaled triple therapy (ICS/LAMA/LABA) as backbone (fx:fda-trelegy-2017, fx:fda-breztri-2020), with roflumilast for severe chronic bronchitis (fx…

[23:30:46] **💾 A3 · Product profile · h2 · commit**
    Saved the product profile. The product must have:
       • Demonstrated ≥20% reduction in annualised moderate/severe exacerbations vs placebo on top of triple therapy in the subgroup with blood eosinophils <300 cells/u…
       • Subcutaneous administration with a dosing interval of at least 4 weeks (i.e., no more frequent than monthly) to ensure adherence and competitiveness with other…
    Gap in standard of care at launch: By 2026-2028, standard of care for COPD will include inhaled triple therapy (ICS/LAMA/LABA) from GSK (Trelegy) and AstraZeneca (Breztri), and oral roflumilast (Daliresp) for severe chronic bronchitis…

[23:30:46] **🔎 A6 · Red team · h3 · retrieve**
    I searched for evidence and kept 10 document(s). These are the only sources I may cite.
    Newest documents:
       • TSLP in a murine smoke-exposure model [fx:pm-tslp-mouse-2019, 2019-11-20]
       • Type 2 inflammation in a subset of COPD [fx:pm-type2-copd-2019, 2019-06-12]
       • Benralizumab in COPD (GALATHEA/TERRANOVA) [fx:pm-galathea-2019, 2019-05-20]
       • CXCR2 antagonist danirixin in COPD [fx:pm-danirixin-2019, 2019-04-15]
       • Exacerbation rate as primary endpoint for COPD biologics [fx:pm-endpoint-exac-2019, 2019-03-10] (+5 more)
    Red-team checklist hits: {'prior_failures': 2, 'single_lab_or_unreplicated': 4, 'safety': 2, 'contradictions': 1}

[23:30:46] **🔎 A6 · Red team · h4 · retrieve**
    I searched for evidence and kept 10 document(s). These are the only sources I may cite.
    Newest documents:
       • TSLP in a murine smoke-exposure model [fx:pm-tslp-mouse-2019, 2019-11-20]
       • Benralizumab in COPD (GALATHEA/TERRANOVA) [fx:pm-galathea-2019, 2019-05-20]
       • CXCR2 antagonist danirixin in COPD [fx:pm-danirixin-2019, 2019-04-15]
       • Exacerbation rate as primary endpoint for COPD biologics [fx:pm-endpoint-exac-2019, 2019-03-10]
       • Ensifentrine Phase 2b on top of tiotropium [fx:pm-pde3-4-ph2-2018, 2018-10-01] (+5 more)
    Red-team checklist hits: {'prior_failures': 2, 'single_lab_or_unreplicated': 2, 'safety': 5, 'contradictions': 1}

[23:30:46] **🔎 A6 · Red team · h5 · retrieve**
    I searched for evidence and kept 10 document(s). These are the only sources I may cite.
    Newest documents:
       • ETHOS: triple therapy reduces exacerbations, mortality signal [fx:pm-ethos-2020, 2020-06-24]
       • TSLP in a murine smoke-exposure model [fx:pm-tslp-mouse-2019, 2019-11-20]
       • Benralizumab in COPD (GALATHEA/TERRANOVA) [fx:pm-galathea-2019, 2019-05-20]
       • CXCR2 antagonist danirixin in COPD [fx:pm-danirixin-2019, 2019-04-15]
       • Exacerbation rate as primary endpoint for COPD biologics [fx:pm-endpoint-exac-2019, 2019-03-10] (+5 more)
    Red-team checklist hits: {'prior_failures': 2, 'single_lab_or_unreplicated': 1, 'safety': 5, 'contradictions': 1}

[23:30:46] **🔎 A6 · Red team · h1 · retrieve**
    I searched for evidence and kept 12 document(s). These are the only sources I may cite.
    Newest documents:
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • IL-33 release and ST2 shift in smokers' airways [fx:pm-il33-smoke-2020, 2020-03-03]
       • TSLP in a murine smoke-exposure model [fx:pm-tslp-mouse-2019, 2019-11-20]
       • Benralizumab in COPD (GALATHEA/TERRANOVA) [fx:pm-galathea-2019, 2019-05-20]
       • CXCR2 antagonist danirixin in COPD [fx:pm-danirixin-2019, 2019-04-15] (+7 more)
    Red-team checklist hits: {'prior_failures': 2, 'single_lab_or_unreplicated': 2, 'safety': 5, 'contradictions': 1}

[23:30:46] **🔎 A6 · Red team · h2 · retrieve**
    I searched for evidence and kept 9 document(s). These are the only sources I may cite.
    Newest documents:
       • TSLP in a murine smoke-exposure model [fx:pm-tslp-mouse-2019, 2019-11-20]
       • Benralizumab in COPD (GALATHEA/TERRANOVA) [fx:pm-galathea-2019, 2019-05-20]
       • CXCR2 antagonist danirixin in COPD [fx:pm-danirixin-2019, 2019-04-15]
       • Exacerbation rate as primary endpoint for COPD biologics [fx:pm-endpoint-exac-2019, 2019-03-10]
       • Quantitative CT as a trial enrichment tool in COPD [fx:pm-ct-imaging-2018, 2018-08-02] (+4 more)
    Red-team checklist hits: {'prior_failures': 2, 'single_lab_or_unreplicated': 4, 'safety': 5, 'contradictions': 1}

[23:30:46] **📝 A6 · Red team · h3 · prompt**
    I wrote the prompt: 2 messages, about 12,110 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:30:46] **📝 A6 · Red team · h4 · prompt**
    I wrote the prompt: 2 messages, about 10,622 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:30:46] **📝 A6 · Red team · h5 · prompt**
    I wrote the prompt: 2 messages, about 11,635 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:30:46] **📝 A6 · Red team · h1 · prompt**
    I wrote the prompt: 2 messages, about 12,345 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:30:46] **📝 A6 · Red team · h2 · prompt**
    I wrote the prompt: 2 messages, about 10,205 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:31:14] **🤖 A6 · Red team · h4 · llm**  _27618 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 27618 ms, 2886 tokens in / 4941 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h4", "verdict": "revise", "revise_target": "a2_mechanism", "risks": [ { "text": "The dual PDE4B/D mechanism is self-limiting: PDE4D inhibition is the known driver of emesis and GI intolerance, as see…”
    Its reasoning (first lines): “We need output JSON only. Need follow schema. Need address reviewer feedback: "why copd, which drugs should i look at, and which companies?" We need incorporate in risks? Probably in text. Need produce verdict. Let's analyze. Hypothesis: PDE4B/D inhibition for COPD. Evidence: roflumilast approved, …”

[23:31:26] **🤖 A6 · Red team · h5 · llm**  _39688 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 39688 ms, 3157 tokens in / 8589 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h5", "verdict": "survives", "revise_target": null, "risks": [ { "text": "Efficacy on top of triple therapy is unproven. Phase 2b (fx:pm-pde3-4-ph2-2018) showed FEV1 improvement on top of tiotropium, …”
    Its reasoning (first lines): “We need to output JSON verdict. Need to follow instructions. We are Agent 6, red teamer. Need to steelman bear case, then verdict. Need to address checklist findings explicitly. Need to cite evidence pack only. Need to produce JSON with risks, kill_criterion, cheapest_test, claims, premortem, verdi…”

[23:31:29] **🤖 A6 · Red team · h3 · llm**  _43094 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 43094 ms, 3428 tokens in / 8937 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h3", "verdict": "survives", "revise_target": null, "risks": [ { "text": "The strongest bear case is that eosinophil/type2 inflammation is a marker, not a driver, of COPD exacerbations. Benralizumab (…”
    Its reasoning (first lines): “We need answer JSON. Need follow instructions. Need use evidence pack only. Need address reviewer feedback: why COPD, which drugs, companies. But output only JSON matching Verdict schema. Need include risks etc. Need decide verdict. Let's analyze. We are Red Teamer. Hypothesis h3: IL4R/IL13 blockad…”

[23:31:40] **🤖 A6 · Red team · h1 · llm**  _26272 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 26272 ms, 3437 tokens in / 6580 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h1", "verdict": "revise", "revise_target": "a3_profile", "risks": [ { "text": "Prior failure of anti-IL5RA (benralizumab) in eosinophilic COPD (fx:pm-galathea-2019) and modest/inconsistent anti-IL5 r…”
    Its reasoning (first lines): “We need to produce a JSON verdict. We are Agent 6, Red Teamer. Need to steelman bear case, then decide verdict. Must address checklist findings, translation risk, competitive risk, product profile must-haves. Then verdict: survives, revise, or kill. Need to output JSON with risks, kill_criterion, c…”

[23:31:54] **🤖 A6 · Red team · h2 · llm**  _28264 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 28264 ms, 2728 tokens in / 7240 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h2", "verdict": "survives", "revise_target": null, "risks": [ { "text": "Translation from asthma to COPD may fail. The only human efficacy evidence for TSLP inhibition is in asthma (PATHWAY), where t…”
    Its reasoning (first lines): “We need to produce a JSON verdict for hypothesis h2: TSLP inhibition for COPD. We have evidence pack and input. We must follow the instructions: Step 1 steelman bear case, Step 2 verdict. We need to output JSON with risks, kill_criterion, cheapest_test, claims, premortem, and verdict fields. Also a…”

[23:31:54] **🧩 A6 · Red team · h3 · parse**
    The answer matches the expected schema. Its verdict is 'survives' with 5 risk(s).

[23:31:54] **🧩 A6 · Red team · h4 · parse**
    The answer matches the expected schema. Its verdict is 'revise' with 4 risk(s).

[23:31:54] **🧩 A6 · Red team · h5 · parse**
    The answer matches the expected schema. Its verdict is 'survives' with 5 risk(s).

[23:31:54] **🧩 A6 · Red team · h1 · parse**
    The answer matches the expected schema. Its verdict is 'revise' with 4 risk(s).

[23:31:54] **🧩 A6 · Red team · h2 · parse**
    The answer matches the expected schema. Its verdict is 'survives' with 5 risk(s).

[23:31:54] **📏 A6 · Red team · h3 · validate**
    The output passes this agent's own quality bars.

[23:31:54] **📏 A6 · Red team · h4 · validate**
    The output passes this agent's own quality bars.

[23:31:54] **📏 A6 · Red team · h5 · validate**
    The output passes this agent's own quality bars.

[23:31:54] **📏 A6 · Red team · h1 · validate**
    The output passes this agent's own quality bars.

[23:31:54] **📏 A6 · Red team · h2 · validate**
    The output passes this agent's own quality bars.

[23:31:55] **✅ A6 · Red team · h3 · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:31:55] **✅ A6 · Red team · h4 · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:31:55] **✅ A6 · Red team · h5 · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:31:55] **✅ A6 · Red team · h1 · postcheck**
    Citation check made 1 change(s): the model cited things it wasn't given, or claimed too much.
       • a6-h1-002: removed unknown source(s) fx:ot-2020-11

[23:31:55] **✅ A6 · Red team · h2 · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:31:55] **💾 A6 · Red team · h3 · commit**
    The red team says: SURVIVES.
       • The strongest bear case is that eosinophil/type2 inflammation is a marker, not a driver, of COPD exacerbations. Benralizumab (anti-IL5RA) depleted eosinophils …
       • Translation from asthma to COPD is unproven. Dupilumab reduced severe exacerbations in asthma, especially with eos>=300, but COPD exacerbations are more hetero…
       • The product profile's must-have of >=30% exacerbation reduction is aggressive and not supported by prior anti-inflammatory trials in COPD. Danirixin (CXCR2 ant… (+2 more)
    Pre-mortem: It is 3 years later and this program failed. The most likely reason was that IL4R/IL13 blockade, like anti-IL5 before it, suppressed type2 biomarkers but did not reduce exacerbations in COPD because eosinophilic inflamm…

[23:31:55] **💾 A6 · Red team · h4 · commit**
    The red team says: REVISE.
       • The dual PDE4B/D mechanism is self-limiting: PDE4D inhibition is the known driver of emesis and GI intolerance, as seen with roflumilast. The product profile's…
       • Efficacy on top of triple therapy is unproven. Roflumilast was approved based on trials that predate the current standard of single-inhaler triple therapy (ICS…
       • Competitive risk from inhaled PDE3/4 inhibition: ensifentrine, a nebulized dual PDE3A/PDE4B inhibitor, improves FEV1 with low GI effects. If ensifentrine or an… (+1 more)
    Pre-mortem: It is 3 years later and this program failed. The most likely reason was that the dual PDE4B/D inhibitor reproduced roflumilast's GI intolerability, leading to high dropout and failure to meet the ≤10% GI discontinuation…

[23:31:55] **💾 A6 · Red team · h5 · commit**
    The red team says: SURVIVES.
       • Efficacy on top of triple therapy is unproven. Phase 2b (fx:pm-pde3-4-ph2-2018) showed FEV1 improvement on top of tiotropium, but no exacerbation data. The mus…
       • Cardiac safety from PDE3A inhibition. Systemic exposure could cause inotropy and arrhythmias. Inhaled delivery may limit this, but the must-have MACE HR upper …
       • Competitive and timing risk. Ensifentrine is the only late-stage PDE3/PDE4 inhibitor; if it fails, the mechanism is likely dead. The drug to watch is ensifentr… (+2 more)
    Pre-mortem: It is 3 years later and this program failed. The most likely reason was that ENHANCE-1 did not demonstrate a meaningful reduction in exacerbations on top of triple therapy, with the incremental benefit of PDE3/PDE4 inhi…

[23:31:55] **💾 A6 · Red team · h1 · commit**
    The red team says: REVISE.
       • Prior failure of anti-IL5RA (benralizumab) in eosinophilic COPD (fx:pm-galathea-2019) and modest/inconsistent anti-IL5 results (fx:pm-metrex-2017, fx:pm-crl-me…
       • Translation risk: evidence is limited to ex-vivo human lung tissue (fx:pm-il33-smoke-2020) and a single-lab mouse study (fx:pm-tslp-mouse-2019, unreplicated). …
       • Competitive risk: Multiple biologics are in late-stage development for COPD, including dupilumab (BOREAS) targeting eosinophilic COPD, mepolizumab (MATINEE), a… (+1 more)
    Pre-mortem: It is 3 years later and this program failed. The most likely reason was that IL33/ST2 blockade failed to reduce exacerbations in a broad COPD population, mirroring the failure of benralizumab, because the type-2 inflamm…

[23:31:55] **💾 A6 · Red team · h2 · commit**
    The red team says: SURVIVES.
       • Translation from asthma to COPD may fail. The only human efficacy evidence for TSLP inhibition is in asthma (PATHWAY), where tezepelumab reduced exacerbations …
       • The only animal evidence for TSLP blockade in COPD is a single-lab mouse smoke-exposure model that has not been replicated. This is weak evidence for efficacy …
       • Competitive and market risk: The COPD biologic space is crowded, with dupilumab and mepolizumab in phase 3 for eosinophilic COPD (based on product profile). If… (+2 more)
    Pre-mortem: It is 3 years later and this program failed. The most likely reason was that TSLP blockade did not reduce exacerbations in COPD, mirroring the failure of benralizumab, because the driver of COPD exacerbations is not typ…

[23:31:55] **🚦 A6 · Red team · h3 · route**
    Red-team routing decision: h3 · survives → review

[23:31:55] **🚦 A6 · Red team · h4 · route**
    Red-team routing decision: h4 · revise overridden → survives (revise target a2_mechanism is run-wide; not rerun per hypothesis)

[23:31:55] **🚦 A6 · Red team · h5 · route**
    Red-team routing decision: h5 · survives → review

[23:31:55] **🚦 A6 · Red team · h1 · route**
    Red-team routing decision: h1 · revise → back to a3_profile (once)

[23:31:55] **🔎 A3 · Product profile · h1 · retrieve**
    I searched for evidence and kept 13 document(s). These are the only sources I may cite.
    Newest documents:
       • Ensifentrine Phase 3 (ENHANCE-1) [fx:nct-enhance1, 2020-09-01]
       • Approval: budesonide/glycopyrrolate/formoterol for COPD [fx:fda-breztri-2020, 2020-07-23]
       • Mepolizumab in COPD (MATINEE) [fx:nct-matinee, 2019-10-01]
       • Dupilumab in COPD with type 2 inflammation (BOREAS) [fx:nct-boreas, 2019-04-01]
       • FDA declines mepolizumab COPD approval [fx:pm-crl-mepo-2018, 2018-09-07] (+8 more)

[23:31:55] **📝 A3 · Product profile · h1 · prompt**
    I wrote the prompt: 2 messages, about 7,093 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:31:55] **🚦 A6 · Red team · h2 · route**
    Red-team routing decision: h2 · survives → review

[23:32:53] **🤖 A3 · Product profile · h1 · llm**  _58556 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 58556 ms, 2077 tokens in / 16000 out, finish reason 'length'.
       ⚠ the answer was cut off (hit max_tokens); parsing will probably fail.
    Its reasoning (first lines): “We need answer JSON only. Need produce TPP for hypothesis h1. Need use evidence pack only, as of 2021-01-01. Need address reviewer feedback. Need include soc_gap_at_launch, minimum_specs, holy_grail_specs, must_haves, expansion_opportunity. Need cite source_ids for evidence claims, reasoning with […”

[23:32:53] **🧩 A3 · Product profile · h1 · parse**
    The answer was not valid JSON for the schema, so I'll give the model the error and retry once.
       1 validation error for ProductProfile Invalid JSON: EOF while parsing a value at line 1 column 0 [type=json_invalid, input_value='', input_type=str] For further information visit https://errors.pydantic.dev/2.11/v/json_invalid

[23:32:53] **🔧 A3 · Product profile · h1 · fix**
    schema error appended to the prompt. Calling the model again with that note.

[23:33:11] **🤖 A3 · Product profile · h1 · llm**  _17323 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 17323 ms, 2156 tokens in / 4244 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h1", "soc_gap_at_launch": "By 2026-2028, standard of care for COPD with exacerbation history will include inhaled triple therapy (ICS/LAMA/LABA) as backbone (fx:fda-trelegy-2017, fx:fda-breztri-2020)…”
    Its reasoning (first lines): “We need to produce JSON for the ProductProfile schema. The user provided the task and evidence. We need to output only JSON. The previous attempt failed because it was empty? Actually the error says "Invalid JSON: EOF while parsing a value at line 1 column 0" meaning the response was empty. So we n…”

[23:33:11] **🧩 A3 · Product profile · h1 · parse**
    The answer matches the expected schema. It lists 2 must-have(s).

[23:33:11] **📏 A3 · Product profile · h1 · validate**
    The output passes this agent's own quality bars.

[23:33:11] **✅ A3 · Product profile · h1 · postcheck**
    Citation check made 6 change(s): the model cited things it wasn't given, or claimed too much.
       • a3-h1-001: removed unknown source(s) fx:pm-il33-smoke-2020
       • a3-h1-001: no valid source left, so it is now 'reasoning' with confidence capped at 0.5
       • a3-h1-002: removed unknown source(s) fx:chembl-itepekimab, fx:chembl-astegolimab
       • a3-h1-002: no valid source left, so it is now 'reasoning' with confidence capped at 0.5
       • a3-h1-003: removed unknown source(s) fx:ot-2020-11 (+1 more)

[23:33:11] **💾 A3 · Product profile · h1 · commit**
    Saved the product profile. The product must have:
       • Demonstrate >=30% reduction in annualized moderate/severe exacerbation rate vs placebo on top of triple therapy at 52 weeks in a biomarker-selected population …
       • Subcutaneous dosing with a frequency of no more than once every 4 weeks.
    Gap in standard of care at launch: By 2026-2028, standard of care for COPD with exacerbation history will include inhaled triple therapy (ICS/LAMA/LABA) as backbone (fx:fda-trelegy-2017, fx:fda-breztri-2020). Roflumilast is available …

[23:33:11] **🔎 A6 · Red team · h1 · retrieve**
    I searched for evidence and kept 9 document(s). These are the only sources I may cite.
    Newest documents:
       • IL-33 release and ST2 shift in smokers' airways [fx:pm-il33-smoke-2020, 2020-03-03]
       • TSLP in a murine smoke-exposure model [fx:pm-tslp-mouse-2019, 2019-11-20]
       • Benralizumab in COPD (GALATHEA/TERRANOVA) [fx:pm-galathea-2019, 2019-05-20]
       • CXCR2 antagonist danirixin in COPD [fx:pm-danirixin-2019, 2019-04-15]
       • Exacerbation rate as primary endpoint for COPD biologics [fx:pm-endpoint-exac-2019, 2019-03-10] (+4 more)
    Red-team checklist hits: {'prior_failures': 2, 'single_lab_or_unreplicated': 2, 'safety': 5, 'contradictions': 1}

[23:33:11] **📝 A6 · Red team · h1 · prompt**
    I wrote the prompt: 2 messages, about 12,008 characters. It includes feedback from a reviewer / the red team. Sending it to the model next.

[23:33:46] **🤖 A6 · Red team · h1 · llm**  _34996 ms_
    The model (deepseek-ai/DeepSeek-V4-Flash-0731) answered in 34996 ms, 3244 tokens in / 7249 out, finish reason 'stop'.
    Start of its raw answer: “{ "hypothesis_id": "h1", "verdict": "revise", "revise_target": "a3_profile", "risks": [ { "text": "The product profile's must-have depends on a serum IL33/sST2 biomarker threshold, but no evidence in the pack shows that…”
    Its reasoning (first lines): “We need answer JSON. Need follow instructions. Need use evidence pack only. Need address checklist findings explicitly. Need produce verdict schema. Need decide survives/revise/kill. Need reason. We are Agent 6 red teamer. Hypothesis: IL33/ST2 axis inhibition for COPD. Evidence tier 2 silver. Need …”

[23:33:46] **🧩 A6 · Red team · h1 · parse**
    The answer matches the expected schema. Its verdict is 'revise' with 5 risk(s).

[23:33:46] **📏 A6 · Red team · h1 · validate**
    The output passes this agent's own quality bars.

[23:33:46] **✅ A6 · Red team · h1 · postcheck**
    Citation check: every claim cites a document that was in the evidence pack. Nothing changed.

[23:33:46] **💾 A6 · Red team · h1 · commit**
    The red team says: REVISE.
       • The product profile's must-have depends on a serum IL33/sST2 biomarker threshold, but no evidence in the pack shows that serum IL33 or soluble ST2 is stable, r…
       • Prior failure of eosinophil-targeting biologics in COPD: GALATHEA/TERRANOVA showed anti-IL5RA (benralizumab) did not reduce exacerbations despite profound eosi…
       • Translation risk: the only human data are genetic association and ex-vivo tissue studies; there is no human RCT evidence for IL33/ST2 blockade in COPD. The sin… (+2 more)
    Pre-mortem: It is 3 years later and this program failed. The most likely reason was that the serum IL33/sST2 biomarker did not enrich for responders, so the phase 2/3 trial was underpowered and showed no significant exacerbation re…

[23:33:46] **🚦 A6 · Red team · h1 · route**
    Red-team routing decision: h1 · revise overridden → survives (revise cap reached (one round))

[23:33:46] **📄 Report**
    Run finished. Wrote the workbook, report.md, steps.md, chat.md, log.md and result.json to person3/langgraph-person3/runs/75a887be-a20b-4dcc-9d57-b90aa238c6b5.

